Key Points {#FPar1}
==========

Compared to first- or second-line of treatment, NSCLC patients who had received PD-1/PD-L1-directed immune checkpoint inhibitor monotherapy in line ≥ three had significantly inferior PFS and OS.In multivariate analyses among all patients, PFS was significantly influenced by PD-L1 expression and ECOG performance status, for OS only therapy line was shown to have a significant impact.In first-line treated patients, PFS was significantly influenced by PD-L1 expression, while there were no significant multivariate findings for first-line OS and second-line PFS/OS. In ≥ third-line patients, ECOG performance status significantly affected PFS and OS.

Introduction {#Sec1}
============

Inhibition of programmed death-ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) has fundamentally changed lung cancer therapy \[[@CR1]\]. Currently, literally any patient with advanced non-small-cell lung cancer (NSCLC) without contraindications will---given a sufficiently long survival period---receive immune checkpoint inhibitor (ICI) treatment at some point during the course of disease. Still, only a minority of patients actually benefit from ICI monotherapy, and foreseeing the individual patient's response is difficult \[[@CR2]\].

Since the advent of ICI therapies for NSCLC, ICI monotherapy has been widely applied, especially in second-line settings following progression after first-line chemotherapy \[[@CR1], [@CR3]--[@CR6]\] or in first-line therapy for highly PD-L1-expressing tumors \[[@CR7]\]. Recently, combinations of ICI and platinum-based doublet chemotherapy have been established as the first-line standard for stage IV NSCLC \[[@CR8], [@CR9]\]. Also, quadruple combinations including bevacizumab have entered daily clinical practice, especially in EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) mutant patients with no more options for tyrosine kinase inhibitor (TKI) therapy \[[@CR10]\]. The value of ICI/ICI combination therapy, however, has not yet been fully clarified, but data are promising \[[@CR11]\].

Despite these rapidly evolving combination regimens, a considerable percentage of patients will still receive ICI monotherapy, especially heavily pretreated patients in third- or later-line settings who have not received ICI therapy before. Patients in these situations are usually characterized by lower performance status, co-morbidities, and treatment-related toxicities restricting available treatment options. Evidence on known predictors of response like PD-L1 expression, EGFR mutational status, or tumor mutational burden (TMB) is mainly derived from first- or second-line therapy studies \[[@CR7], [@CR11], [@CR12]\]. Thus, it appears questionable if those biomarkers have the same prognostic and/or predictive properties in third- or later-line therapy settings.

Our aim was to evaluate whether response to PD-1/PD-L1 ICI monotherapy changes with therapy line and which patient or tumor-related factors are associated with patient outcomes in a real-life setting.

Patients and Methods {#Sec2}
====================

One hundred and fifty-three consecutive patients with advanced NSCLC who had received at least one cycle of nivolumab, pembrolizumab, or atezolizumab at the lung cancer unit of Kepler University Hospital Linz and the medical oncology unit of Paracelsus Medical University Salzburg between May 2015 and June 2018 were retrospectively registered.

First-line therapy was defined as primary treatment in a non-curable (e.g., stage IV \[[@CR13]\] or not otherwise treatable stage III) setting, not considering previous therapies in potentially curable stages. Patients in stage III disease were eligible to receive ICI therapy and to be included in the study if they were pre-treated by chemo(radio)therapy and another line of chemotherapy was not reasonably feasible. Also, in selected cases upon contraindications to chemotherapy and despite PD-L1 \< 50%, a first-line ICI treatment in stage IV disease could be applied after multidisciplinary tumor-board discussion. We excluded patients in clinical trials, on ICI/chemotherapy or ICI/ICI combinations, and those who received ICI for thoracic malignancies other than NSCLC.

Patients were retrospectively followed from ICI therapy initiation to death or censored at the date of the last verified contact. The time of disease progression was retrospectively defined by imaging and death, as well as by the patients' medical records. In selected cases of considerable clinical benefit, ICI therapy could be applied beyond the determined point of disease progression. Radiological response was routinely assessed by an iodinated contrast medium-enhanced CT scan of the chest and the upper abdomen after four cycles of nivolumab or three cycles of pembrolizumab/atezolizumab, equaling a time interval of 10 or 12 weeks, respectively. Re-staging could be preponed in case of clinical suspicion of disease progression, and additional/alternative imaging modalities like ^18^F-FDG-PET/CT or cerebral magnetic resonance tomography could be applied if necessary, according to the clinician's judgment. For this study, radiological response was re-evaluated by an expert thoracic radiologist and graded by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 \[[@CR14]\] for first and best response (CR---complete remission, PR---partial remission, SD---stable disease, PD---progressive disease). Overall response rate (ORR) was defined as the percentage of patients having reached a best response of CR or PR.

Kaplan--Meier-analyses for PFS and OS were conducted for all patients and according to therapy line (first line, second line, ≥ third line). Results were expressed as median in months \[95% confidence interval (CI)\], unless otherwise specified. The Kaplan--Meier survival curves were compared statistically using the log rank test, and a *p* value \< 0.05 was regarded as statistically significant.

Evaluation of predictive factors for PFS and OS was conducted applying uni- and multivariate Cox-regression analyses. Variables analyzed in these models were age groups (\</≥ 70 years), sex, histological subtype (adeno-, squamous-cell carcinoma), presence of brain metastases, palliative therapy line (1 vs. 2, ≥ 3), ECOG (Eastern Cooperative Oncology Group) performance status (0 vs. 1, 2, 3) and presence of a targetable genetic tumor alteration (ALK, EGFR, ROS). PD-L1 expression on tumor cells was assessed with a 22C3 assay for Autostainer Link 48 by Dako (Agilent Technologies, Santa Clara, CA, USA), whereas a negative PD-L1 status was defined as a proportion of \< 1% of viable tumor cells showing membranous staining.

Results {#Sec3}
=======

Baseline patient and tumor characteristics for all patients and according to therapy line are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline patient and tumor characteristics for all patients and according to therapy lineAll patients (*N* = 153)First-line therapy (*N* = 45)Second-line therapy (*N* = 70)≥ Third-line therapy (*N* = 38)Age (mean, SD)66 (11)72 (10)66 (9)61 (12)Age range (years)26--9047--9039--8526--81ECOG status 045 (29)16 (36)17 (24)12 (29) 191 (59)27 (60)44 (63)20 (60) 214 (10)1 (2)9 (13)4 (9) 33 (2)1 (2)02 (2)Sex Female62 (41)19 (42)28 (40)15 (40) Male91 (59)26 (58)42 (60)23 (60)ICI substance Nivolumab80 (52)16 (36)37 (53)27 (71) Pembrolizumab58 (38)26 (58)26 (37)6 (16) Atezolizumab15 (10)3 (7)7 (10)5 (13)Smoking status Never/≤ 5 py20 (13)5 (11)8 (11)7 (18)  \> 5 py123 (80)40 (89)56 (80)27 (71) Unknown10 (7)6 (9)4 (11) Total py (mean, SD)44 (34)43 (25)48 (39)38 (35)Histology Adenocarcinoma100 (65)19 (42)49 (79)32 (84) Squamous cell carcinoma53 (35)26 (58)21 (30)6 (16)TNM stage III19 (12)14 (31)3 (4)2 (5) IV134 (88)31 (69)67 (96)36 (95) CNS involvement31 (20)4 (9)16 (23)11 (29)Genetic alteration EGFR13 (8)4 (6)9 (24) ALK2 (1)2 (5) ROS13 (2)3 (4)PD-L1 status Not available21 (14)2 (4)10 (14)9 (24) Positive85 (56)30 (67)42 (60)13 (34) Negative47 (31)13 (29)18 (26)16 (42)PD-L1 expression Not available24 (16)3 (7)12 (17)9 (24)  \< 1%47 (31)13 (29)18 (26)16 (42) 1--49%44 (29)13 (29)24 (34)7 (18)  ≥ 50%38 (25)16 (36)16 (23)6 (16)Figures are given as absolute number and percent within the respective group unless otherwise specified. The numeric discrepancies between PD-L1 status and PD-L1 expression are due to patients with pathologically determined positive PD-L1 status but without exact quantification being reported or with further quantification being impossible (*n* = 3)*SD* standard deviation, *ECOG* Eastern Cooperative Oncology Group, *ICI* immune checkpoint inhibitor, *py* pack years, *TNM* TNM Classification of Malignant Tumours, *CNS* central nervous system, *EGFR* epidermal growth factor receptor, *ALK* Anaplastic Lymphoma Kinase, *ROS1* proto-oncogene tyrosine-protein kinase ROS, *PD*-*L1* Programmed Death-Ligand 1

PFS and OS as well as radiological response in all patients and according to the respective therapy line are shown in Table [2](#Tab2){ref-type="table"}. Kaplan--Meier analyses (Fig. [1](#Fig1){ref-type="fig"}) showed that therapy line significantly influenced PFS (*p* = 0.003) and OS (*p* = 0.001). A univariate Cox-regression analysis confirmed that patients in ≥ third-line treatment had a significant disadvantage concerning PFS (*p* = 0.005) and OS (*p* = 0.002). For patients in ≥ third-line therapy, hazard ratio (HR) was 1.97 (1.20--3.21; *p* = 0.007) for PFS and 1.99 (1.12--3.53; *p* = 0.019) for OS as compared to first-line therapy. Second-line compared to first-line therapy did not pose a significant risk for inferior PFS \[HR 1.02 (0.65--1.60; *p* = 0.941)\] or OS \[HR 0.82 (0.46--1.46; *p* = 0.493)\].Table 2Radiological first and best response, objective response rate, progression-free and overall survival in all patients and according to therapy lineAll patients (*N* = 153)First-line therapy (*N* = 45)Second-line therapy (*N* = 70)≥ Third-line therapy (*N* = 38)First response (RECIST) Not available34 (22)3 (7)25 (36)6 (16) Complete remission1 (1)1 (1) Partial remission25 (16)12 (27)9 (13)4 (11) Stable disease40 (26)15 (33)14 (20)11 (29) Progressive disease53 (35)15 (33)21 (30)17 (45)Best response (RECIST) Not available34 (22)3 (7)25 (36)6 (16) Complete remission3 (2)1 (2)1 (1)1 (3) Partial remission31 (20)15 (33)12 (17)4 (11) Stable disease33 (22)11 (24)13 (19)9 (24) Progressive disease52 (34)15 (33)19 (27)18 (47)Objective response (rate in %)34 (22)16 (36)13 (19)5 (13)Median progression-free survival (95% CI)4 (3, 5)7 (3, 11)4 (3, 7)2 (1, 3)Median overall survival (95% CI)13 (10, 17)17 (9, --)18 (13, --)9 (4, 12)Figures are given as absolute number and percent within the respective group unless otherwise specified. *Objective response rate* includes patients with a RECIST best response of complete or partial remission*RECIST* Response Evaluation Criteria in Solid Tumors, *CI* confidence intervalFig. 1Kaplan--Meier curves for progression-free (**a**) and overall (**b**) survival according to therapy line. *NA* not available, *CI* confidence interval

In the whole patient cohort, the multivariate model (Table [3](#Tab3){ref-type="table"}) revealed that PFS was significantly influenced by PD-L1 status (*p* = 0.002) and ECOG performance status (*p* = 0.029). For OS, the only significant variable identified was therapy line (*p* = 0.025).Table 3Uni- and multivariate analyses for progression-free and overall survival according for all patientsVariableProgression-free survivalOverall survivalUnivariateMultivariateUnivariateMultivariateHR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*Age ≥ 70 vs. \< 70 years0.98 (0.68--1.42)0.2651.06 (0.67--1.67)0.800Female vs. male0.81 (0.56--1.17)0.2650.96 (0.61--1.51)0.866ECOG 1 vs. 00.85 (0.56--1.29)0.4410.81 (0.52--1.27)0.3591.25 (0.74--2.10)0.407ECOG 2 vs. 0**1.88 (1.00**--**3.52)0.049**1.01 (0.45--2.24)0.987**2.66 (1.16**--**6.11)0.021**ECOG 3 vs. 0**7.38 (2.21**--**24.67)0.0017.13 (1.65**--**30.73)0.008**3.51 (0.82--15.09)0.092Therapy line 2 vs. 11.02 (0.65--1.60)0.9410.83 (0.47--1.49)0.5340.83 (0.47--1.49)0.534Therapy line 3 vs. 1**2.00 (1.20**--**3.21)0.0072.00 (1.13**--**3.54)0.0182.00 (1.13--3.54)0.018**PD-L1 status (neg. vs. ≥ 1%)**1.95 (1.30**--**2.92)0.0012.04 (1.32**--**3.17)0.002**1.60 (0.98--2.61)0.062Mutational status (pos. vs. neg.)**1.84 (1.09**--**3.09)0.023**1.53 (0.80--2.90)0.198CNS involvement (yes vs. no)1.22 (0.79--1.89)0.3681.26 (0.74--2.16)0.398Squamous vs. adenocarinoma0.88 (0.60--1.29)0.4950.93 (0.57--1.50)0.750Figures are given as hazard ratio (95% confidence interval), with a ratio \> 1 signifying an increased risk of progression/deathBold values are statistically significant (*p* \< 0.05)*HR* hazard ratio, *CI* confidence interval, *ECOG* Eastern Cooperative Oncology Group, *PD*-*L1* programmed death-ligand 1, *CNS* central nervous system

For first-line therapy patients, the multivariate Cox-regression analysis revealed a negative PD-L1 status as significant predictor of PFS (*p* = 0.006), while for OS no variable was significant. In the second-line setting, no variable had significant impact on either PFS or OS. In third-line therapy, both PFS and OS (both *p* \< 0.001) were significantly determined by ECOG performance status. A significant signal for inferior OS in squamous-cell carcinoma patients in the univariate analysis could not be re-enacted in the multivariate evaluation (Table [4](#Tab4){ref-type="table"}).Table 4Uni- and multivariate analyses for progression-free and overall survival according to therapy lineFirst-line therapySecond-line therapyThird-line therapyUnivariateMultivariateUnivariateMultivariateUnivariateMultivariateHR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*HR (95% CI)*p*Progression-free survival Age ≥ 70 vs. \< 70 years0.99 (0.45--2.14)0.9851.27 (0.72--2.23)0.404**1.09 (0.49**--**2.45)0.045** Female vs. male0.78 (0.37--1.66)0.5530.82 (0.47--1.43)0.4830.76 (0.38--1.49)0.421 ECOG 1 vs. 01.55 (0.67--3.60)0.3050.71 (0.36--1.38)0.3100.83 (0.40--1.75)0.6290.83 (0.40--1.75)0.629 ECOG 2 vs. 03.34 (0.40--27.90)0.2661.63 (0.69--3.83)0.2621.88 (0.58--6.08)0.2911.88 (0.58--6.08)0.291 ECOG 3 vs. 04.00 (0.47--33.65)0.204//**20.7 (2.70**--**159)0.00420.7 (2.70**--**159)0.004** PD-L1 status (neg vs. ≥ 1%)**3.27 (1.40**--**7.65)0.0063.27 (1.40**--**7.65)0.006**1.81 (0.97--3.36)0.0611.08 (0.49--2.36)0.857 Mutational status (pos. vs. neg.)//1.41 (0.60--3.33)0.4301.54 (0.72--3.27)0.263 CNS involvement (yes vs. no)1.65 (0.57--4.77)0.3600.75 (0.39--1.47)0.4021.87 (0.89--3.90)0.098 Squamous vs. adenocarinoma0.74 (0.35--1.50)0.7411.14 (0.64--2.04)0.2032.43 (0.98--6.04)0.057Overall survival Age ≥ 70 vs. \< 70 years0.82 (0.32--2.10)0.6841.26 (0.59--2.69)0.5462.45 (1.01--5.94)0.048 Female vs. male1.21 (0.49--2.99)0.6761.06 (0.51--2.23)0.8700.66 (0.31--1.39)0.272 ECOG 1 vs. 02.53 (0.83--7.71)0.1021.17 (0.47--2.94)0.7411.07 (0.48--2.37)0.8681.07 (0.48--2.37)0.868 ECOG 2 vs. 03.06 (0.34--27.62)0.3192.33 (0.65--8.40)0.197**6.18 (1.43**--**26.66)0.0156.18 (1.43**--**26.66)0.015** ECOG 3 vs. 0////**58.09 (4.66--724)0.00258.09 (4.66--724)0.002** PD-L1 status (neg vs. ≥ 1%)1.71 (0.66--4.41)0.2731.71 (0.74--3.96)0.2091.15 (0.50--2.63)0.748 Mutational status (pos. vs. neg.)//1.26 (0.38--4.21)0.7031.09 (0.48--2.49)0.835 CNS involvement (yes vs. no)0.97 (0.22--4.24)0.9691.20 (0.51--2.84)0.6741.89 (0.77--4.68)0.166 Squamous vs. adenocarinoma0.51 (0.20--1.27)0.1491.23 (0.57--2.66)0.601**6.12 (2.14**--**17.53)\< 0.001**Figures are given as hazard ratio (95% confidence interval), with a ratio \> 1 signifying an increased risk of progression/deathBold values are statistically significant (*p* \< 0.05)*HR* hazard ratio, *CI* confidence interval, *ECOG* Eastern Cooperative Oncology Group, *PD*-*L1* programmed death-ligand 1, *CNS* central nervous system

Discussion {#Sec4}
==========

Our data suggest that patients receiving single-agent PD-1/PD-L1 ICI therapy in ≥ third-line therapy have significantly inferior PFS and OS compared to first- or second-line treatment. While "traditional" predictive factors like PD-L1 expression are relevant for PFS in first-line treated patients, they seem to have less impact in third- or later-line-treated patients, where only ECOG performance status had significant implications on PFS and OS.

Most phase 3 clinical trials that finally led to the approval of nivolumab, pembrolizumab, and atezolizumab were open for patients with more than one prior line of therapy. As an exception, CheckMate-057 only included second-line patients and CheckMate-017 only allowed for additional TKI therapy or switch maintenance. All those studies had an emphasis on second-line patients, as shown in Table [5](#Tab5){ref-type="table"} \[[@CR3]--[@CR6], [@CR15]--[@CR20]\]. Generally, ORR, PFS, and OS decreased with increasing number of previous therapy lines, which is consistent with our findings. Reported outcomes concerning PFS and OS tend to partly surpass our results; however, this may reflect the difference between a real-life cohort and a clinical trial setting. Of note, the mentioned trials included, with very few exceptions, only patients with ECOG performance status 0 or 1. On the contrary, our reported collective comprised 10% of ECOG 2 and 2% of ECOG 3 patients. Thus, an OS of 9 months in a ≥ third-line setting appears to be a very promising result, while the comparatively short PFS of only 2 months requires further considerations: The natural course of disease in a third-line therapy stage IV NSCLC setting has itself never been studied to our knowledge. There was, however, a placebo arm in a study by Shepherd et al. (2005) evaluating erlotinib in chemotherapy-pretreated NSCLC patients, of which nearly 50% were ≥ third-line patients. Patients allocated to the placebo group had an OS of 4.7 months and a PFS of 1.8 months \[[@CR21]\]. The question arises how our reported ≥ third-line collective could have witnessed an obviously longer OS, but a PFS not better than placebo. On the one hand, patients who reached such advanced therapy lines tended to be younger, as mean age decreased with therapy line (72 years in first-, 66 years in second-, and 61 years in ≥ third-line patients), whereas ECOG distribution did not show such a trend. On the other hand, the relatively high number of patients with activating alterations in EGFR or ALK in therapy line ≥ 3 (*N* = 11, 29%) may have influenced outcomes. Surprisingly, however, we did not find a significant association of either PFS or OS with the presence of that known predictive factor in uni- and multivariate analyses. It is likely that patients with such targetable genetic alterations in higher therapy lines may have received less cytotoxic chemotherapies due to available target therapy options and thus still had further and broader treatment options. Of those 11 patients in our collective, 8 (73%) received further therapy, as compared to 11 of 26 (42%) in the non-mutant patient group. As response rates to ICI mono-therapy in more advanced therapy lines \[[@CR3], [@CR6], [@CR15], [@CR16]\] as well as in EGFR- or ALK-mutant patients are known to be only modest \[[@CR12]\], PFS in ≥ third-line therapy is thus expectedly low. However, in our comparably young and frequently EGFR-mutant ≥ third-line collective, it seems that a considerable OS could still be attained with subsequent chemo- or target therapies after progression on ICI treatment.Table 5Overview of relevant clinical phase 3 trials (framed) as well as trials reporting advanced therapy-line outcomes for single-agent PD-L1/PD-1 directed monotherapy in non-small-cell lung cancerStudy namePhaseSubstance/comparatorHistological subtypeAdvanced therapy line patients (%)Reported outcomes with emphasis on advanced therapy linesCheckMate-017 \[[@CR4]\]3Nivolumab/docetaxelSquamous NSCLC progressing after first-line chemotherapy271 (100%) second-line patientsMedian OS for nivolumab 9.2 mo (7.3--13.3) vs. 6 mo (5.1--7.3) for docetaxel; ORR 20% for nivolumab vs. 9% for docetaxelNo patients in therapy line \> 2CheckMate-057 \[[@CR3]\]3Nivolumab/docetaxelNon-squamous NSCLC after doublet platinum-based chemotherapy515 (89%) second line, 66 (11%) third lineMedian OS for nivolumab 12.2 mo (9.7--15), 9.4 mo (8.1--10.7) for docetaxel; ORR 19% for nivolumab vs. 12% for docetaxelSecond-line therapy: OS HR for nivolumab vs. docetaxel 0.69 (0.56--0.85); third-line therapy: 1.34 (0.73--2.43)KEYNOTE-010 \[[@CR5]\]2/3Pembrolizumab (2 or 10 mg/kg)/docetaxelPreviously treated PD-L1-positive, advanced NSCLC713 (69%) second-line, 210 (20%) third- and 90 (8%) fourth-line patientsMedian OS for pembrolizumab 2 mg/kg 10.4 mo (9.4--11.9), 12.7 mo (10.0--17.3) for pembrolizumab 10 mg/kg and 8.5 mo (7.5, 9.8) for docetaxel. No therapy-line specific outcomes reportedOAK \[[@CR6]\]3Atezolizumab/docetaxelPreviously treated NSCLC210 (25%) third-line patientsOS HR for atezolizumab vs. docetaxel 0.71 (0.59--0.86) in second line and 0.8 (0.57--1.12) in third line. Median OS for atezolizumab 15.2 mo in third line, 12.8 mo in second lineKEYNOTE-001 \[[@CR15]\]1PembrolizumabAdvanced NSCLC74 (14.9%) second line, 119 (24%) third line, 106 (21.4%) fourth line, 102 (20.6%) \< fourth linePD-L1 ≥ 50% previously treated: ORR 43.9%; treatment naïve: ORR 50%PD-L1 1-49% previously treated: ORR 15.6% (8.3--25.6); treatment naïve: ORR 19.2%PD-L1 \< 1% previously treated: ORR 9.1%; treatment naïve: ORR 16.7%BIRCH study \[[@CR16]\]2AtezolizumabAdvanced NSCLC142 (21%) first line, 271 (41%) second line, 254 (38%) ≥ third lineFirst-line therapy: ORR 22%, OS 20.1 mo (20.1--n.e.); second-line: ORR 19%, OS 15.5 mo (12.3--n.e.), ≥ third-line: ORR 18%, OS 13.2 mo (10.3--17.5). EGFR or ALK alterations in the subgroups: 11%, 8%, and 7%, respectivelyPOPLAR \[[@CR17]\]2Atezolizumab/docetaxelPreviously treated NSCLC189 (66%) second- and 98 (34%) third-line patientsAtezolizumab: 12.6 mo (9.7--16.4), PFS 2.7 mo (0.72--1.23), ORR 15%. Docetaxel: OS 9.7 (8.6--12), PFS 3 mo (0.72--1.23), ORR 15%. Results stratified according to therapy line were not reportedMDX1106-03 \[[@CR18]\]1Nivolumab (1, 3, or 10 mg/kg)Previously treated advanced NSCLC59 (45.7%) second line, 70 (54.3%) ≥ third lineMedian OS for all patients and doses: 9 mo (2.8--12.4), ORR: 17.1%. ORR for ≥ third-line patients: 21%CheckMate-063 \[[@CR19]\]2NivolumabAdvanced pretreated (≥ 2 lines) squamous NSCLC41 (35%) third line, 52 (44%) fourth line, 24 (21%) ≥ fifth lineMedian OS for all patients: 8.2 mo (6.1--10.9), PFS 1.9 mo (1.8--3.2), ORR: 17.5%No results according to therapy line reportedATLANTIC \[[@CR20]\]2DurvalumabAdvanced NSCLC, ≥ 2 previous therapy lines179 (40%) third line, 121 (27%) fourth line, 144 (32%) ≥ fifth lineEGFR/ALK pos. PD-L1 \< 25%: ORR 3.6%, OS 9.9 mo (4.2--13), PFS 1.9 mo (1.8--1.9)EGFR/ALK pos. PD-L1 ≥ 25%: ORR 12.2%, OS 13.3 mo (8.1--), PFS 1.9 mo (1.8--3.6)EGFR/ALK neg. PD-L1 \< 25%: ORR 7.5%, OS 9.3 mo (5.9--10.8), PFS 1.9 (1.8--1.9)EGFR/ALK neg. PD-L1 ≥ 25%: ORR 16.4%, OS 10.9 mo (8.6--13.6), PFS 3.3 mo (1.9, 3.7)EGFR/ALK neg. PD-L1 ≥ 90%: ORR 30.9%, OS n.r., PFS 2.4 mo (1.8--5.5)*NSCLC* non-small-cell lung cancer, *OS* overall survival, *M* months, *OS* overall survival, *PFS* progression-free survival, *HR* hazard ratio, *ORR* overall response rate, *PD*-*L1* programmed death-ligand 1, *EGFR* epidermal growth factor receptor, *ALK* anaplastic lymphoma kinase

Of interest, the ATLANTIC study on durvalumab evaluated a very similar patient collective of heavily pretreated and frequently EGFR- or ALK-positive patients, and reported results very similar to ours (Table [5](#Tab5){ref-type="table"}) \[[@CR20]\]. Also, Lin et al. recently published data on a real-world ICI monotherapy cohort of 74 patients receiving nivolumab or pembrolizumab, of which 41% were EGFR mutant, 49% had an ECOG status ≥ 2, and 69% received ICI therapy in ≥ third-line therapy. The authors reported an ORR of 32%, PFS was 1.8, and OS 7.8 months. In a multivariate Cox-proportional hazards analysis, ECOG ≥ 2 significantly influenced PFS (HR 9.13) and OS (HR 14.72), whereas ICI therapy in ≥ third-line therapy did not significantly impact PFS and OS. Analogously to our reported results, Lin et al. found no meaningful influence of EGFR mutation on the cohort outcomes, with a HR of 2.00 (*p* = 0.022---univariate) and 1.26 (*p* = 0.534---multivariate) for PFS and 1.07 for OS (univariate), though there expectedly was a significantly lower treatment response in the EGFR-mutant group with an odds ratio of 0.09 (*p* = 0.043) \[[@CR22]\].

Our study has several limitations. The retrospective design and the relatively small sample size together with numeric differences between the subgroups limited the significance of subgroup analyses. Also, the inclusion criteria may have limited the study results, and a relatively high percentage of stage III patients received first-line mono-ICI treatment and a few patients also received such therapy due to contraindications to chemotherapy despite a PD-L1 expression \< 50%. Another possible limitation is that the re-staging schedule differed slightly between nivolumab (10 weeks) and pembrolizumab/atezolizumab (12 weeks). As 71% of patients in ≥ third-line treatment received nivolumab, a shorter PFS could partly be explained by that fact. Besides those methodological limitations, the current therapeutic landscape in NSCLC has clearly shifted away from second- or later-line ICI application, as reported in this cohort, to first-line therapy, either in combination with chemotherapy or alone in highly PD-L1-expressing tumors. In line with these recent developments, our reported results support ICI application earlier rather than later in therapy. Still, advances in molecular or clinical characterization of NSCLC patients may again alter the current therapeutic approach, so that our present data could be of value for future considerations.

We conclude that the efficacy of single-agent PD-1/PD-L1 therapy is lower when applied in more advanced therapy lines (≥ 3). The prognostic value of "traditional" biomarkers like PD-L1 expression or presence of a targetable alteration in EGFR or ALK seems to diminish in third or later therapy lines, where PFS and OS were mainly determined by patient performance status.
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